Combination of Calcipotriene 0.05% Foam and Halobetasol Propionate 0.05% Foam in the Treatment of Scalp Psoriasis

Main Article Content

A Young
Core Assistant Professor, Department of Internal Medicine, Hackensack-Meridian School of Medicine Assistant Clinical Professor of Dermatology, Department of Dermatology, Columbia University Medical Center

R Schreiber
Director of Medical Affairs at Mayne Pharma

Keywords

Psoriasis, Calcipotriene, Halobetasol

Abstract

Abstract not available.

References

1. National Psoriasis Foundation. (2019, July 31). About Psoriasis. Retrieved from Psoriasis.Org: www.psoriasis.org/parents/about-psoriasis.
2. American Academy of Dermatology. (n.d.). Psoriasis clinical guideline. Retrieved December 24, 2019, from aad.org: https://www.aad.org/member/clinical-quality/guidelines/psoriasis.
3. Gudjonsson, J. E., & Elder , J. T. (2019). Chapter 28: Psoriasis. In S. Kang, M. Amagai, A. L. Bruckner, & et al (Eds.), Fitzpatrick's Dermatology (9 ed.). New York, NY: McGraw Hill.
4. Mayne Pharma. (2019, May14). SORILUX Prescribing Information. Greenville, NC.
5. Mayne Pharma. (2019, April). Halobetasol Foam, 0.05% Prescribing Information. Greenville, NC.
6. Mayne Pharma. (2019). Data on file.
7. Van de Kerkhof, P. C. (2001). Therapeutic strategies: Rotational therapy and combinations. Clin Exp Dermatol, 26, 356.
8. Stein Gold, L., Horgan,A., Schreiber, R., & Ye, R. (2019). Determination of the In Vitro Chemical Compatibility of Calcipotriene Foam, 0.005%, in Combination with Halobetasol ProprionateFoam, 0.05%. Winter Clinical Dermatology Conference. Kawaii, HI: FRED.

Article Sidebar

Poster PDF
Published
Jan 28, 2020

Article Details

How to Cite
[1]
Young, A. and Schreiber, R. 2020. Combination of Calcipotriene 0.05% Foam and Halobetasol Propionate 0.05% Foam in the Treatment of Scalp Psoriasis. SKIN The Journal of Cutaneous Medicine. 4, 1 (Jan. 2020), S3.
Issue
Vol. 4 No. 1 (2020): January Issue & Poster Presentations (2020 Winter Clinical Dermatology Conference®)
Section
Poster Presentations at 2020 Winter Clinical Dermatology Conference®: Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.